Loading...

Quanterix Corporation

QTRXNASDAQ
Healthcare
Medical - Devices
$4.83
$-0.01(-0.21%)

Quanterix Corporation (QTRX) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Quanterix Corporation (QTRX), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
10.68%
10.68%
Operating Income Growth
-18.37%
18.37%
Net Income Growth
-19.17%
19.17%
Operating Cash Flow Growth
-86.03%
86.03%
Operating Margin
-71.77%
71.77%
Gross Margin
55.54%
55.54%
Net Profit Margin
-56.23%
56.23%
ROE
-22.07%
22.07%
ROIC
-27.48%
27.48%

Quanterix Corporation (QTRX) Income Statement & Financial Overview

Review Quanterix Corporation QTRX income statement with detailed quarterly and annual figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$30.33M$35.16M$35.41M$34.38M
Cost of Revenue$13.92M$12.99M$15.66M$14.32M
Gross Profit$16.41M$22.17M$19.75M$20.06M
Gross Profit Ratio$0.54$0.63$0.56$0.58
R&D Expenses$10.04M$8.07M$8.10M$8.10M
SG&A Expenses$32.46M$28.87M$23.80M$25.06M
Operating Expenses$42.49M$34.44M$31.50M$32.91M
Total Costs & Expenses$56.41M$46.34M$47.16M$47.49M
Interest Income$3.27M$3.49M$3.54M$3.68M
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$0.00$3.62M$776000.00$2.44M
EBITDA-$26.37M-$11.15M-$10.97M-$10.67M
EBITDA Ratio-$0.87-$0.32-$0.31-$0.31
Operating Income-$26.37M-$14.77M-$11.75M-$13.11M
Operating Income Ratio-$0.87-$0.42-$0.33-$0.38
Other Income/Expenses (Net)$2.95M$3.13M$3.54M$3.67M
Income Before Tax-$23.42M-$11.64M-$8.21M-$9.44M
Income Before Tax Ratio-$0.77-$0.33-$0.23-$0.27
Income Tax Expense$2.91M-$8000.00$145000.00$37000.00
Net Income-$20.50M-$11.63M-$8.35M-$9.47M
Net Income Ratio-$0.68-$0.33-$0.24-$0.28
EPS-$0.53-$0.30-$0.22-$0.25
Diluted EPS-$0.53-$0.30-$0.22-$0.25
Weighted Avg Shares Outstanding$38.72M$38.55M$38.45M$38.34M
Weighted Avg Shares Outstanding (Diluted)$38.72M$38.55M$38.45M$38.34M

Financial performance has remained strong, with revenue growing from $34.38M in Q2 2024 to $30.33M in Q1 2025. Gross profit continued to perform well, with margins at 54% in the latest quarter. Operating income reached -$26.37M in Q1 2025, holding a steady -87% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$26.37M. Net income dropped to -$20.50M, keeping EPS at -$0.53. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;